Compound comparisons
Choosing between two compounds usually comes down to one mechanistic difference. Each page below puts a pair side by side — receptors, presentation, availability and price — and explains what actually separates them.
All comparisons
How a dual GIP/GLP-1 agonist differs from a single GLP-1 agonist: receptor targets, molecular design, half-life and the trials behind each compound.
Read the guide Metabolic ResearchRetatrutide vs TirzepatideA triple agonist against the dual incretin agonist — what the third receptor changes.
Compare Metabolic ResearchRetatrutide vs SemaglutideThree receptors against one — the widest mechanistic gap in the GLP-1 class.
Compare Metabolic ResearchSemaglutide vs LiraglutideTwo GLP-1 agonists from the same family, separated mainly by half-life.
Compare Metabolic ResearchOral Semaglutide vs SemaglutideThe same molecule in two delivery routes — and why the oral dose is so much larger.
Compare Metabolic ResearchCagriSema vs TirzepatideAn amylin/GLP-1 co-formulation against a dual incretin agonist.
Compare Metabolic ResearchSurvodutide vs RetatrutideDual GLP-1/glucagon against the triple agonist that adds GIP.
Compare Metabolic ResearchVK2735 vs TirzepatideTwo dual GIP/GLP-1 agonists at very different stages of development.
Compare Metabolic ResearchOrforglipron vs SemaglutideA non-peptide oral GLP-1 agonist against the injectable peptide standard.
Compare Recovery ResearchBPC-157 vs TB-500The two most-studied repair peptides — different origins, frequently examined together.
Compare Growth ResearchCJC-1295 (with DAC) vs IpamorelinTwo growth hormone secretagogues that work on opposite halves of the same axis.
Compare Cosmetic ResearchGHK-Cu vs AHK-CuTwo copper-binding tripeptides studied in different tissues.
Compare Cellular ResearchMOTS-C vs SS-31Two mitochondrial peptides that intervene at completely different levels.
Compare Neuro ResearchSemax vs SelankTwo Russian-developed neuropeptides with distinct research profiles.
Compare